{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:16Z","timestamp":1791475456638,"version":"4.3.4"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n<jats:title><jats:italic>Context:<\/jats:italic><\/jats:title>\n<jats:p>Growth hormone (GH) deficiency is a common late effect of cranial irradiation. However, concerns have been raised that GH treatment might lead to an increased risk of a second neoplasm (SN).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Objective:<\/jats:italic><\/jats:title>\n<jats:p>To study the impact of GH treatment on the risk of SN in a French cohort of survivors of childhood cancer (CCS) treated before 1986.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Design and setting:<\/jats:italic><\/jats:title>\n<jats:p>Cohort study and nested case\u2013control study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Participants:<\/jats:italic><\/jats:title>\n<jats:p>Of the 2852 survivors, with a median follow-up of 26 years, 196 had received GH therapy (median delay from cancer diagnosis: 5.5 years).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Main outcome measures:<\/jats:italic><\/jats:title>\n<jats:p>Occurrence of SN<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Results:<\/jats:italic><\/jats:title>\n<jats:p>In total, 374 survivors developed a SN, including 40 who had received GH therapy. In a multivariate analysis, GH treatment did not increase the risk of secondary non-meningioma brain tumors (RR: 0.6, 95% CI: 0.2\u20131.5, <jats:italic>P<\/jats:italic>\u2009=\u20090.3), secondary non-brain cancer (RR: 0.7, 95% CI: 0.4\u20131.2, <jats:italic>P<\/jats:italic>\u2009=\u20090.2), or meningioma (RR: 1.9, 95% CI: 0.9\u20134, <jats:italic>P<\/jats:italic>\u2009=\u20090.09). Nevertheless, we observed a slight non-significant increase in the risk of meningioma with GH duration: 1.6-fold (95% CI: 1.2\u20133.0) after an exposure of less than 4 years vs 2.3-fold (95% CI: 0.9\u20135.6) after a longer exposure (<jats:italic>P<\/jats:italic> for trend\u2009=\u20090.07) confirmed by the results of a case\u2013control study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title><jats:italic>Conclusion:<\/jats:italic><\/jats:title>\n<jats:p>This study confirms the overall safety of GH use in survivors of childhood cancer, which does not increase the risk of a SN. The slight excess in the risk of meningioma in patients with long-term GH treatment is non-significant and could be due to difficulties in adjustment on cranial radiation volume\/dose and\/or undiagnosed meningioma predisposing conditions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-20-0369","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T16:47:05Z","timestamp":1596127625000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":18,"title":["Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer"],"prefix":"10.1093","volume":"183","author":[{"given":"C\u00e9cile","family":"Thomas-Teinturier","sequence":"first","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"3Department of Pediatric Endocrinology, AP-HP, Universit\u00e9 Paris Saclay, site Bicetre, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Oliver-Petit","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Endocrinology, Children Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Pacquement","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Fresneau","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"6Department of Pediatrics Oncology, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue S\u00e9tch\u00e9ou","family":"Allodji","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"7Department of Research Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Veres","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"7Department of Research Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bolle","sequence":"additional","affiliation":[{"name":"8Department of Radiotherapy Oncology, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Berchery","sequence":"additional","affiliation":[{"name":"9Centre Claudius R\u00e9gaud, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Demoor-Goldschmidt","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"10Department of Pediatrics Oncology, CHU Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Haddy","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"7Department of Research Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Diallo","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"7Department of Research Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"de Vathaire","sequence":"additional","affiliation":[{"name":"1Cancer and Radiation, CESP, Unit 1018 INSERM, Villejuif, France"},{"name":"2University Paris-Saclay, Villejuif, France"},{"name":"7Department of Research Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/183\/4\/EJE-20-0369.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/183\/4\/EJE-20-0369.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:14:58Z","timestamp":1676391298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/183\/4\/471\/6653720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje-20-0369","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}